Ethnic differences in pharmacogenetically relevant genes

R. M. Engen, S. Marsh, D. J. Van Booven, H. L. McLeod*

*Corresponding author for this work

Research output: Contribution to journalReview article

50 Citations (Scopus)

Abstract

There is great heterogeneity in the way humans respond to medications, often requiring empirical strategies to define the appropriate drug therapy for each patient. Genetic polymorphisms in drug metabolizing enzymes, transporters, receptors, and other drug targets provide putative markers for predicting which patients will experience extreme toxicity and treatment failure. Both quantitative (allele frequency) and qualitative (specific allele) differences for polymorphic genes have been observed between different population groups. For example, the frequency of mutations in thiopurine methyltransferase is lower in Chinese than Caucasian populations. In addition, the predominant mutation responsible for deficient enzyme activity differs between the two populations (TPMT*3C versus TPMT*3A). Understanding the influence of ethnicity on pharmacogenomics will allow for comprehensive strategies for using the genome to optimize therapy for patients throughout the world.

Original languageEnglish (US)
Pages (from-to)1641-1648
Number of pages8
JournalCurrent Drug Targets
Volume7
Issue number12
DOIs
StatePublished - Dec 1 2006

Fingerprint

thiopurine methyltransferase
Genes
Drug therapy
Enzyme activity
Polymorphism
Pharmaceutical Preparations
Toxicity
Drug Receptors
Pharmacogenetics
Genetic Polymorphisms
Mutation Rate
Enzymes
Treatment Failure
Population Groups
Gene Frequency
Population
Alleles
Genome
Drug Therapy
Mutation

Keywords

  • ABCB1
  • Ethnicity
  • Pharmacogenetics
  • Pharmacogenomics
  • TPMT
  • TYMS
  • VKORC1

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Engen, R. M. ; Marsh, S. ; Van Booven, D. J. ; McLeod, H. L. / Ethnic differences in pharmacogenetically relevant genes. In: Current Drug Targets. 2006 ; Vol. 7, No. 12. pp. 1641-1648.
@article{39daad7f93794940a02fdec09e79800a,
title = "Ethnic differences in pharmacogenetically relevant genes",
abstract = "There is great heterogeneity in the way humans respond to medications, often requiring empirical strategies to define the appropriate drug therapy for each patient. Genetic polymorphisms in drug metabolizing enzymes, transporters, receptors, and other drug targets provide putative markers for predicting which patients will experience extreme toxicity and treatment failure. Both quantitative (allele frequency) and qualitative (specific allele) differences for polymorphic genes have been observed between different population groups. For example, the frequency of mutations in thiopurine methyltransferase is lower in Chinese than Caucasian populations. In addition, the predominant mutation responsible for deficient enzyme activity differs between the two populations (TPMT*3C versus TPMT*3A). Understanding the influence of ethnicity on pharmacogenomics will allow for comprehensive strategies for using the genome to optimize therapy for patients throughout the world.",
keywords = "ABCB1, Ethnicity, Pharmacogenetics, Pharmacogenomics, TPMT, TYMS, VKORC1",
author = "Engen, {R. M.} and S. Marsh and {Van Booven}, {D. J.} and McLeod, {H. L.}",
year = "2006",
month = "12",
day = "1",
doi = "10.2174/138945006779025446",
language = "English (US)",
volume = "7",
pages = "1641--1648",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "12",

}

Ethnic differences in pharmacogenetically relevant genes. / Engen, R. M.; Marsh, S.; Van Booven, D. J.; McLeod, H. L.

In: Current Drug Targets, Vol. 7, No. 12, 01.12.2006, p. 1641-1648.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Ethnic differences in pharmacogenetically relevant genes

AU - Engen, R. M.

AU - Marsh, S.

AU - Van Booven, D. J.

AU - McLeod, H. L.

PY - 2006/12/1

Y1 - 2006/12/1

N2 - There is great heterogeneity in the way humans respond to medications, often requiring empirical strategies to define the appropriate drug therapy for each patient. Genetic polymorphisms in drug metabolizing enzymes, transporters, receptors, and other drug targets provide putative markers for predicting which patients will experience extreme toxicity and treatment failure. Both quantitative (allele frequency) and qualitative (specific allele) differences for polymorphic genes have been observed between different population groups. For example, the frequency of mutations in thiopurine methyltransferase is lower in Chinese than Caucasian populations. In addition, the predominant mutation responsible for deficient enzyme activity differs between the two populations (TPMT*3C versus TPMT*3A). Understanding the influence of ethnicity on pharmacogenomics will allow for comprehensive strategies for using the genome to optimize therapy for patients throughout the world.

AB - There is great heterogeneity in the way humans respond to medications, often requiring empirical strategies to define the appropriate drug therapy for each patient. Genetic polymorphisms in drug metabolizing enzymes, transporters, receptors, and other drug targets provide putative markers for predicting which patients will experience extreme toxicity and treatment failure. Both quantitative (allele frequency) and qualitative (specific allele) differences for polymorphic genes have been observed between different population groups. For example, the frequency of mutations in thiopurine methyltransferase is lower in Chinese than Caucasian populations. In addition, the predominant mutation responsible for deficient enzyme activity differs between the two populations (TPMT*3C versus TPMT*3A). Understanding the influence of ethnicity on pharmacogenomics will allow for comprehensive strategies for using the genome to optimize therapy for patients throughout the world.

KW - ABCB1

KW - Ethnicity

KW - Pharmacogenetics

KW - Pharmacogenomics

KW - TPMT

KW - TYMS

KW - VKORC1

UR - http://www.scopus.com/inward/record.url?scp=33745150832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745150832&partnerID=8YFLogxK

U2 - 10.2174/138945006779025446

DO - 10.2174/138945006779025446

M3 - Review article

C2 - 17168839

AN - SCOPUS:33745150832

VL - 7

SP - 1641

EP - 1648

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 12

ER -